HIV Drugs Reach 8 Million in Needy Countries
By Agence
France-Presse (MSN)
July 18, 2012
Sub-Saharan Africa
HIV drugs
reach 8 million in needy countries (MSN)
The
rise in drug coverage in 2011 was
accompanied by a dramatic 31 percent drop
in deaths from AIDS-related causes in
sub-Saharan Africa, the area of the world
most ravaged by the disease, compared to
the peak of the epidemic in 2005.
In all low- and middle-income countries,
the availability of antiretroviral drugs
grew by more than 20 percent in just one
year, over the latest figure of 6.6
million people covered in 2010, said the
report.
Now, more than half (54 percent) of the
estimated 14.8 million people in need of
antiretrovirals in those countries can
access them, according to the figures
released in Washington ahead of the
International AIDS Conference next week.
The report said the advance "puts the
international community on track to reach
the goal of 15 million people with HIV
receiving treatment by 2015," an aim
unanimously agreed by UN member states.
"But access (to treatment) is not
universal. We still have a problem with
access in Asia, in Eastern Europe, Central
Asia so we need to redouble the effort,"
said UNAIDS Executive Director Michel
Sidibe.
Those parts of the world are seeing deaths
and new infections rise "in a very
alarming way," he said.
More governments have stepped up funding
to help those suffering within their own
borders, with 81 countries increasing
their domestic investments for AIDS by
more than 50 percent between 2006 and
2011.
Overall, low- and middle- income countries
invested $8.6 billion in responding to
HIV/AIDS last year, an increase of 11
percent over 2010. International funding
remained flat at 2008 levels of $8.2
billion.
Total worldwide investment in HIV totaled
$16.8 billion last year, an 11 percent
rise from 2010, but still far short of the
$22-24 billion needed by 2015, the report
said.
Nearly half (48 percent) of all
international assistance for HIV response
last year came from the United States,
which is hosting the July 22-27 scientific
meeting expected to draw 25,000 people.
US AIDS Coordinator Eric Goosby said
reducing the impact of AIDS worldwide was
a "priority" for the US government and
called for nations to step up their
involvement in local AIDS programs.
"If we do not aggressively move to
work with our colleagues in country to
expand their capacity to manage, oversee,
monitor and evaluate these programs,
regardless of resources we will fail," he
said.
Reacting to the UNAIDS report, Doctors
Without Borders also made a plea for
faster pace in treatment and a boost in
worldwide funding.
"Globally, we're finally past the half-way
mark with HIV treatment, but that still
means almost one in two people don't have
access to the medicines they need to stay
alive," said a statement by Eric Goemaere,
the group's senior HIV/TB adviser in
southern Africa.
"If we're going to reach all people who
need treatment, we have to double the pace
of scale-up and double the funds."
Other highlights of the UNAIDS report
included the drop in the costs of
antiretrovirals, from $10,000 per person
in 2000 to less than $100 per person in
2011 for the least expensive
WHO-recommended regimen.
Fewer children were infected with HIV in
2011 -- about 330,000 worldwide -- down 24
percent from 2009.
But a staggering 3.4 million children
under 15 were living with HIV last year,
91 percent of them in sub-Saharan Africa.
The statistics were alarming for young
women, too, with HIV named as the leading
cause of death in women of reproductive
age globally and those aged 15-24 facing
infection rates that are double those of
males the same age.
An estimated 1.2 million women and girls
were newly infected with HIV last year,
according to the report.
It also hailed studies showing that
treatment with antiretrovirals could
reduce the risk of transmission from an
infected person to a healthy partner by 96
percent.
The report described a "significant
reduction" in transmission to uninfected
people who are at high risk through sexual
activity and who take the drugs as a
preventive measure, though it noted a
"major challenge" in adhering to daily
therapy.
|